NCT02598063View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Adefovir dipivoxil

ADV will be administered orally at a dose of 10 mg QD for 72 weeks.

DRUG

Lamivudine

Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.

Trial Locations (12)

852

Hong Kong

100044

Beijing

100050

Beijing

100054

Beijing

200025

Shanghai

200040

Shanghai

201508

Shanghai

250021

Jinan

310003

Hangzhou

400038

Chongqing

510515

Guangzhou

Unknown

Hong Kong

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02598063 - A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B | Biotech Hunter | Biotech Hunter